Global Footprint MLM operates in Europe and North America, and a recent partnership with Single Cell Discoveries signals enhanced cross-border sample logistics, enabling smoother multiregional studies and faster start-up for US-based programs.

Advanced Capabilities Launch of Panther molecular testing platform at the Memphis facility and investment in Leica Aperio GT-450 scanner expands molecular diagnostics and histology capabilities, enabling more complete data packages for study designs.

Broad Analytical Reach With coverage from nonclinical to phase IV and analysis across 900+ parameters via in vitro and ex vivo models, MLM offers broad, high-resolution data that can underpin decision-making for diverse therapeutic areas.

Strategic Alliances Board expansion with Paul Kirchgraber and ongoing partnerships with Cytespace, Vial, and other clinical trial providers underscore MLM's credibility and potential to serve as a scalable, integrated partner for large pharma and rapid biotech programs.

Growth Opportunity Mid-range revenue and a mid-sized team position MLM as a flexible partner for emerging biotech through Top Ten Pharma, with upsell potential across discovery, preclinical, and late-stage development and expanding service lines such as IPF models and imaging.